ATE442592T1 - Detektion und/oder beobachtung von synuclein- assoziierten krankheiten - Google Patents

Detektion und/oder beobachtung von synuclein- assoziierten krankheiten

Info

Publication number
ATE442592T1
ATE442592T1 AT03709934T AT03709934T ATE442592T1 AT E442592 T1 ATE442592 T1 AT E442592T1 AT 03709934 T AT03709934 T AT 03709934T AT 03709934 T AT03709934 T AT 03709934T AT E442592 T1 ATE442592 T1 AT E442592T1
Authority
AT
Austria
Prior art keywords
synuclein
monitoring
detection
patient
associated diseases
Prior art date
Application number
AT03709934T
Other languages
English (en)
Inventor
David Allsop
Omar M A El-Agnaf
Sultan A Salem
Original Assignee
Lancaster University Business
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9931023&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE442592(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lancaster University Business filed Critical Lancaster University Business
Application granted granted Critical
Publication of ATE442592T1 publication Critical patent/ATE442592T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AT03709934T 2002-02-14 2003-02-14 Detektion und/oder beobachtung von synuclein- assoziierten krankheiten ATE442592T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0203446.0A GB0203446D0 (en) 2002-02-14 2002-02-14 Detection and/or monitoring of synuclein-related diseases
PCT/GB2003/000677 WO2003069332A2 (en) 2002-02-14 2003-02-14 Detection and/or monitoring of synuclein-related diseases

Publications (1)

Publication Number Publication Date
ATE442592T1 true ATE442592T1 (de) 2009-09-15

Family

ID=9931023

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03709934T ATE442592T1 (de) 2002-02-14 2003-02-14 Detektion und/oder beobachtung von synuclein- assoziierten krankheiten

Country Status (9)

Country Link
US (1) US20050176078A1 (de)
EP (1) EP1476758B2 (de)
JP (1) JP2005528588A (de)
AT (1) ATE442592T1 (de)
AU (1) AU2003214364A1 (de)
CA (1) CA2480466C (de)
DE (1) DE60329165D1 (de)
GB (1) GB0203446D0 (de)
WO (1) WO2003069332A2 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040146521A1 (en) * 1999-06-01 2004-07-29 Schenk Dale B. Prevention and treatment of synucleinopathic disease
DE10041478A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
US8697082B2 (en) * 2002-11-01 2014-04-15 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US9034337B2 (en) 2003-10-31 2015-05-19 Prothena Biosciences Limited Treatment and delay of outset of synucleinopathic and amyloidogenic disease
TW200509968A (en) * 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
US8506959B2 (en) * 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US20080014194A1 (en) * 2003-10-31 2008-01-17 Elan Pharmaceuticals, Inc. Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
US7358331B2 (en) * 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
WO2005047860A2 (en) * 2003-11-08 2005-05-26 Elan Pharmaceuticals, Inc. Antibodies to alpha-synuclein
DE10361258A1 (de) 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
DE102004014841B4 (de) 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
ES2310057B1 (es) * 2004-07-19 2009-11-17 Oryzon Genomics, S.A. Metodo de analisis molecular y tratamiento en demencia de cuerpos de lewy.
CN1752104B (zh) * 2004-09-21 2010-05-05 北京市肿瘤防治研究所 突触蛋白γ的单克隆抗体及其应用
CA2657953A1 (en) * 2005-07-19 2007-01-25 University Of Rochester Alpha-synuclein antibodies and methods related thereto
HRP20140049T1 (hr) 2007-01-05 2014-02-28 University Of Zürich Anti beta-amiloid antitijela i njihova upotreba
US8147833B2 (en) * 2007-02-23 2012-04-03 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
PL2118300T3 (pl) * 2007-02-23 2015-11-30 Prothena Biosciences Ltd Zapobieganie i leczenie synukleinopatii i amyloidozy
GB0716885D0 (en) 2007-08-30 2007-10-10 United Arab Emirates Universit Diagnostic agent
WO2010069603A1 (en) 2008-12-19 2010-06-24 Neurimmune Therapeutics Ag Human anti-alpha-synuclein autoantibodies
US20120190652A1 (en) * 2009-09-16 2012-07-26 United Arab Emirates University Diagnostic agent for parkinson's disease
CN101692092B (zh) * 2009-09-24 2013-04-10 首都医科大学宣武医院 定量检测人血清中自体α-突触核蛋白抗体的方法
US10989718B2 (en) 2014-09-11 2021-04-27 Amprion, Inc. Detection of misfolded alpha synuclein protein
JP6006908B2 (ja) * 2010-11-05 2016-10-12 ブランダイス ユニバーシティＢｒａｎｄｅｉｓ Ｕｎｉｖｅｒｓｉｔｙ Ｉｃｅ阻害化合物およびその使用
US20130289022A1 (en) * 2010-11-05 2013-10-31 Brandeis University Tetrameric alpha-synuclein and use thereof
CA2818171A1 (en) * 2010-11-24 2012-06-07 Elan Pharmaceuticals, Inc. Phagocytic activity as a marker of synucleinopathic disease
CN103796679B (zh) 2011-06-23 2016-10-19 比奥根国际神经科学公司 抗-α突触核蛋白结合分子
US20140295465A1 (en) * 2011-11-02 2014-10-02 Biogen Idec International Neuroscience Gmbh USE OF AN ANTI-alpha-SYNUCLEIN ANTIBODY TO DIAGNOSE AN ELEVATED LEVEL OF alpha-SYNUCLEIN IN THE BRAIN
ES2481517B1 (es) * 2013-01-29 2015-06-01 Universidad De Sevilla Método para el diagnóstico de la enfermedad de parkinson en estadios tempranos
US12265089B2 (en) 2014-09-11 2025-04-01 Board Of Regents Of The University Of Texas System Discriminating Parkinson's disease from multiple system atrophy using alpha-synuclein PMCA
EP3191599B1 (de) * 2014-09-11 2023-08-02 Board Of Regents Of the University Of Texas System Detektion von fehlgefalteten proteinen
JP6564032B2 (ja) 2014-11-14 2019-08-21 ユナイテッド アラブ エミレーツ ユニバーシティＵｎｉｔｅｄ Ａｒａｂ Ｅｍｉｒａｔｅｓ Ｕｎｉｖｅｒｓｉｔｙ 造影剤用の化合物
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
CN104711280B (zh) * 2014-12-10 2018-04-13 中国医学科学院医学生物学研究所 表达和纯化同时缺失外显子3和5 的α突触核蛋白选择性剪切体蛋白的方法
TW201901153A (zh) 2017-05-16 2019-01-01 美商安培恩股份有限公司 折疊錯誤之ｔａｕ蛋白的檢測及檢測折疊錯誤之ｔａｕ蛋白的套組
BR112019027029A2 (pt) * 2017-06-19 2020-07-14 Kainos Medicine, Inc. moduladores de alfa-sinucleina
AU2018321335B2 (en) 2017-08-22 2025-08-14 Biogen Ma Inc. Pharmaceutical compositions containing anti-beta amyloid antibodies
JP7173532B2 (ja) * 2018-08-28 2022-11-16 学校法人順天堂 α－シヌクレイノパチーの診断
RU2703430C1 (ru) * 2018-12-13 2019-10-16 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр глазных болезней имени Гельмгольца" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ ГБ им. Гельмгольца" Минздрава России) Способ прогнозирования развития нейродегенеративных заболеваний, в основе патогенеза которых лежит гамма-синуклеинопатия
EP3779448A1 (de) * 2019-08-12 2021-02-17 Baden-Württemberg Stiftung gGmbH Neuartiger diagnostischer marker für die creutzfeldt-jakob-krankheit und morbus-alzheimer
EP4111197A1 (de) * 2020-02-25 2023-01-04 Markus Otto Diagnose einer mit synaptischer degeneration assoziierten erkrankung mittels elisa zur bestimmung einer beta-synuklein-konzentration in csf
WO2022115705A2 (en) 2020-11-30 2022-06-02 Enigma Biointelligence, Inc. Non-invasive assessment of alzheimer's disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5602042A (en) * 1994-04-14 1997-02-11 Cytyc Corporation Method and apparatus for magnetically separating biological particles from a mixture
AU3117799A (en) * 1998-03-30 1999-10-18 Trustees Of The University Of Pennsylvania, The Method of identifying, diagnosing and treating synuclein positive neurodegenerative disorders
ATE312349T1 (de) * 1998-07-03 2005-12-15 Innogenetics Nv Differentielle diagnose von neurodegeneration
WO2002004482A1 (en) * 2000-07-07 2002-01-17 Panacea Pharmaceuticals, Inc. Methods for preventing neural tissue damage and for the treatment of alpha-synuclein diseases
US20020150948A1 (en) * 2000-11-03 2002-10-17 Gerardo Castillo Antibody PTI-HS7 for treatment of alzheimer's disease and other amyloidoses and parkinson's disease

Also Published As

Publication number Publication date
DE60329165D1 (de) 2009-10-22
JP2005528588A (ja) 2005-09-22
US20050176078A1 (en) 2005-08-11
WO2003069332A3 (en) 2004-01-08
AU2003214364A1 (en) 2003-09-04
CA2480466A1 (en) 2003-08-21
EP1476758A2 (de) 2004-11-17
GB0203446D0 (en) 2002-04-03
CA2480466C (en) 2010-12-21
EP1476758B2 (de) 2015-02-11
EP1476758B1 (de) 2009-09-09
WO2003069332A2 (en) 2003-08-21

Similar Documents

Publication Publication Date Title
DE60329165D1 (de) Detektion und/oder beobachtung von synuclein-assoziierten krankheiten
DE60326214D1 (de) Assays zur überwachung von krebspatienten auf grundlage der spiegel von analytenkomponenten des plasminogen-aktivator-systems in proben von körperflüssigkeiten
DE60312309D1 (de) Verwendung von botulinum toxin zur behandlung von herz- und kreislaufskrankheiten
DE60108230D1 (de) Vorrichtung für diagnose und behandlung von arrhytmien
DE602004010407D1 (de) Fluorsubstituierter omega-carboxyaryldiphenylharnstoff zur behandlung und prävention von krankheiten und leiden
CY1110503T1 (el) Πενταμιδινη για θεραπεια καρκινου
EP1583504A4 (de) Verfahren und zusammensetzungen für diagnose, prognose und behandlung von krebs
DE60324180D1 (de) Behandlung der huntington's krankheit mit epa
MX2009005941A (es) Ensayos de diagnostico complementario para terapia de cancer.
EP1501531A4 (de) Verfahren zur behandlung von angst und stimmungsstörungen bei älternen personen
ATE356994T1 (de) Screeningverfahren mit pim1-kinase oder pim3- kinase
ATE430935T1 (de) Nachweis und behandlung von prostatakrebs
EA200870088A1 (ru) Применение бензоконденсированных гетероциклических сульфамидных производных для понижения уровней липидов и глюкозы в крови
DE60327530D1 (de) Plasma urotensin und menschliche herzerkrankung
DE60122673D1 (de) Methoden zur diagnose und behandlung von herzkrankheiten
ATE520987T1 (de) Verfahren zum nachweis und/oder screening zur überwachung eines kolorektalkrebs in einem individuum
WO2006047475A3 (en) Detection and analysis of ophthalmically-relevant fluorescent molecules
ATE552776T1 (de) Verfahren und vorrichtung zur überwachung eines sedierten patienten
ATE393243T1 (de) Diagnostisches verfahren der mastozytose
AU2003272189A8 (en) Caspase inhibitors for the treatment of diseases and conditions caused by exposure to radionuclides, biological agents, or chemical agents
EP1363528A4 (de) Verfahren zur diagnose und behandlung von herzerkrankungen
ATE554790T1 (de) Verfahren und zusammensetzungen zur diagnose von asthma
DE50210987D1 (de) Verbindungen zur beseitigung und/oder linderung der anhedonie
WO2004034994A3 (en) Methods and compositions for determining risk of treatment toxicity
DE60225845D1 (de) Zusammensetzungen und verfahren zur diagnose und behandlung von diabetes, insulinresistenz und dyslipidämie

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties